应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
LEGN 传奇生物
未开盘 07-10 16:00:00 EDT
27.08
-0.30
-1.10%
盘后
27.08
+0.00
0.00%
17:28 EDT
最高
27.53
最低
26.52
成交量
134.30万
今开
27.45
昨收
27.38
日振幅
3.69%
总市值
52.38亿
流通市值
24.42亿
总股本
1.93亿
成交额
3,630万
换手率
1.49%
流通股本
9,019万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Calidi Biotherapeutics任命前基因泰克/罗氏与Celgene高管Corsee Sanders博士加入董事会
美股速递 · 06-23
Calidi Biotherapeutics任命前基因泰克/罗氏与Celgene高管Corsee Sanders博士加入董事会
异动解读｜传奇生物盘中上涨5.44%，2.26亿美元ADS发行落地叠加淋巴瘤疗法积极临床数据提振
行情直击 · 06-23
异动解读｜传奇生物盘中上涨5.44%，2.26亿美元ADS发行落地叠加淋巴瘤疗法积极临床数据提振
港股异动 | 金斯瑞生物科技(01548)一度跌超10% 传奇生物淋巴瘤疗法研究客观缓解率达100%
智通财经 · 06-15
港股异动 | 金斯瑞生物科技(01548)一度跌超10% 传奇生物淋巴瘤疗法研究客观缓解率达100%
传奇生物(LEGN.US)：2个月内，股价如何从5日拉升40%到单日拉升超40%？
智通财经 · 06-05
传奇生物(LEGN.US)：2个月内，股价如何从5日拉升40%到单日拉升超40%？
港股异动 | 金斯瑞生物科技(01548)高开近15% 传奇生物披露治疗淋巴瘤初步临床数据显示积极信号
智通财经 · 06-03
港股异动 | 金斯瑞生物科技(01548)高开近15% 传奇生物披露治疗淋巴瘤初步临床数据显示积极信号
热门中概股普涨 传奇生物(LEGN)涨 8.98% 三倍做多富时中国ETF涨8.40%
金吾财讯 · 06-02
热门中概股普涨 传奇生物(LEGN)涨 8.98% 三倍做多富时中国ETF涨8.40%
传奇生物：剂量水平2队列实现100%客观缓解率，复发/难治性NHL患者完全缓解率达83.3%
美股速递 · 06-02
传奇生物：剂量水平2队列实现100%客观缓解率，复发/难治性NHL患者完全缓解率达83.3%
传奇生物：数据显示无需淋巴清除化疗或桥接治疗即可实现强劲的体内CAR-T扩增
美股速递 · 06-02
传奇生物：数据显示无需淋巴清除化疗或桥接治疗即可实现强劲的体内CAR-T扩增
港股异动 | 金斯瑞生物科技(01548)涨超5% 近日联营传奇生物多项研究成果于2026年ASCO年会发布
智通财经 · 05-27
港股异动 | 金斯瑞生物科技(01548)涨超5% 近日联营传奇生物多项研究成果于2026年ASCO年会发布
传奇生物(LEGN)盘中上涨1.71% 机构指Carvykti为多发性骨髓瘤领域同类最佳CAR-T疗法
金吾财讯 · 05-14
传奇生物(LEGN)盘中上涨1.71% 机构指Carvykti为多发性骨髓瘤领域同类最佳CAR-T疗法
港股异动 | 金斯瑞生物科技(01548)涨超5% 联营传奇生物一季度亏损收窄、CARVYKTI®净销售额增六成
智通财经 · 05-13
港股异动 | 金斯瑞生物科技(01548)涨超5% 联营传奇生物一季度亏损收窄、CARVYKTI®净销售额增六成
传奇生物公布截至2026年3月31日现金、现金等价物及定期存款达8.346亿美元
美股速递 · 05-12
传奇生物公布截至2026年3月31日现金、现金等价物及定期存款达8.346亿美元
传奇生物Q1 2026财报前瞻：CARVYKTI销售额预计约5.97亿美元
环球市场播报 · 05-11
传奇生物Q1 2026财报前瞻：CARVYKTI销售额预计约5.97亿美元
财报前瞻｜传奇生物本季度营收预计同比增58.58%，机构观点偏积极
财报Agent · 05-05
财报前瞻｜传奇生物本季度营收预计同比增58.58%，机构观点偏积极
股价5日拉升逾40%，礼来的70亿美元豪赌让市场看清低估的传奇生物(LEGN.US)？
智通财经 · 04-22
股价5日拉升逾40%，礼来的70亿美元豪赌让市场看清低估的传奇生物(LEGN.US)？
港股异动 | 金斯瑞生物科技(01548)涨超5% 年度收益同比增加61.4% 传奇生物亏损大幅收窄
智通财经 · 03-17
港股异动 | 金斯瑞生物科技(01548)涨超5% 年度收益同比增加61.4% 传奇生物亏损大幅收窄
【新股IPO】据报传奇生物计划今年在香港上市 集资3亿至4亿美元
金吾财讯 · 03-12
【新股IPO】据报传奇生物计划今年在香港上市 集资3亿至4亿美元
传奇生物CAR-T销售放量，盈利拐点将至下的喜与忧
21世纪经济报道 · 03-10
传奇生物CAR-T销售放量，盈利拐点将至下的喜与忧
财报前瞻｜传奇生物营收预计增71.50%，市场观点偏正面
财报Agent · 03-03
财报前瞻｜传奇生物营收预计增71.50%，市场观点偏正面
吉利德78亿美元全面收购Arcellx公司获得BCMA-CAR T疗法
药企市值评估 · 02-27
吉利德78亿美元全面收购Arcellx公司获得BCMA-CAR T疗法
加载更多
公司概况
公司名称：
传奇生物
所属市场：
NASDAQ
上市日期：
--
主营业务：
传奇生物科技有限公司是一家全球性的临床级生物制药公司，致力于肿瘤和其他适应症的新药的发现和开发。该公司的差异化技术、全球开发和制造战略及专业知识使其能够针对高未满足需求的适应症生成、测试和制造下一代细胞疗法。
发行价格：
--
{"stockData":{"symbol":"LEGN","market":"US","secType":"STK","nameCN":"传奇生物","latestPrice":27.08,"timestamp":1783713600000,"preClose":27.38,"halted":0,"volume":1343008,"hourTrading":{"tag":"盘后","latestPrice":27.08,"preClose":27.08,"latestTime":"17:28 EDT","volume":354903,"amount":9610774.146,"timestamp":1783718917995,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.010956902848794766,"floatShares":90192700,"shares":193439800,"eps":-1.380412,"marketStatus":"未开盘","change":-0.3,"latestTime":"07-10 16:00:00 EDT","open":27.45,"high":27.53,"low":26.52,"amount":36296813.770048,"amplitude":0.036888,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.380412,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1783929600000},"marketStatusCode":0,"adr":0,"adrRate":2,"listingDate":1591329600000,"exchange":"NASDAQ","adjPreClose":27.38,"preHourTrading":{"tag":"盘前","latestPrice":27.75,"preClose":27.38,"latestTime":"08:03 EDT","volume":1051,"amount":29164.999862,"timestamp":1783684998346,"change":0.37,"changeRate":0.013514,"amplitude":0.009131},"postHourTrading":{"tag":"盘后","latestPrice":27.08,"preClose":27.08,"latestTime":"17:28 EDT","volume":354903,"amount":9610774.146,"timestamp":1783718917995,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.005933549376323,"impliedVol":0.6765,"impliedVolPercentile":0.8008},"requestUrl":"/m/hq/s/LEGN","defaultTab":"news","newsList":[{"id":"1154584198","title":"Calidi Biotherapeutics任命前基因泰克/罗氏与Celgene高管Corsee Sanders博士加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1154584198","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154584198?lang=zh_cn&edition=full","pubTime":"2026-06-23 20:03","pubTimestamp":1782216238,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics宣布，任命在生物技术领域拥有丰富经验的前基因泰克/罗氏及Celgene公司高管Corsee Sanders博士加入其董事会。此项人事任命旨在强化公司的战略指导与治理能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEGN","BK4585","RARE","CLDI","BK4588","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107737029","title":"异动解读｜传奇生物盘中上涨5.44%，2.26亿美元ADS发行落地叠加淋巴瘤疗法积极临床数据提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1107737029","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107737029?lang=zh_cn&edition=full","pubTime":"2026-06-23 00:49","pubTimestamp":1782146963,"startTime":"0","endTime":"0","summary":"6月22日，传奇生物盘中上涨5.44%，报29.45美元/股，成交额3649.34万美元。消息面上，公司近期完成了770万份美国存托股份的公开发行，定价为每份29.35美元，募资总额约2.26亿美元。融资落地消除不确定性，叠加管线积极数据，市场情绪回暖。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643522150","title":"港股异动 | 金斯瑞生物科技(01548)一度跌超10% 传奇生物淋巴瘤疗法研究客观缓解率达100%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643522150","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643522150?lang=zh_cn&edition=full","pubTime":"2026-06-15 11:20","pubTimestamp":1781493658,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技一度跌超10%，截至发稿，跌8.37%，报11.93港元，成交额2.95亿港元。消息面上，金斯瑞生物科技联营公司传奇生物日前宣布，其针对复发/难治性B细胞非霍奇金淋巴瘤患者的在研体内CD19/CD20双靶点CAR-T细胞疗法LB2501首次临床概念验证数据。在一项正在开展的I期研究中，复发/难治性B细胞非霍奇金淋巴瘤患者接受单次输注后，在第2剂量水平达到了100%的ORR和83.3%的CR率。截至数据截止时，所有缓解仍在持续。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK4139","01548","BK4585","VXUS","BK1583","HK0000306685.HKD","HK0000320223.HKD","BK1141","BK4588","HK0000306701.USD","HK0000320264.USD","LEGN","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641716111","title":"传奇生物(LEGN.US)：2个月内，股价如何从5日拉升40%到单日拉升超40%？","url":"https://stock-news.laohu8.com/highlight/detail?id=2641716111","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641716111?lang=zh_cn&edition=full","pubTime":"2026-06-05 17:58","pubTimestamp":1780653488,"startTime":"0","endTime":"0","summary":"继今年4月20日股价拉升18.42%之后，传奇生物在6月2日再次迎来单日股价“40cm”的暴力拉升时刻以及二级市场的价值重估。6月2日，传奇生物股价暴力拉升“40cm”收涨42.22%，给了前期主力资金拉升出货的一个机会。在可评估的5名患者中，ORR达100%，CR达80%。这一消息直接引发了业界和市场对其现货型CAR-T疗法持久性的质疑，导致其股价短期内大跌超20%。从场内表现来看，6月2日之后，传奇生物股价连续2日回调，分别收跌0.83%和4.85%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450790.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","BK4505","LEGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640927867","title":"港股异动 | 金斯瑞生物科技(01548)高开近15% 传奇生物披露治疗淋巴瘤初步临床数据显示积极信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2640927867","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640927867?lang=zh_cn&edition=full","pubTime":"2026-06-03 09:23","pubTimestamp":1780449806,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技高开近15%，截至发稿，涨14.99%，报13.96港元，成交额617.03万港元。6月2日晚，金斯瑞生物科技公布，美国上市联营公司传奇生物披露在研体内CD19/CD20双靶点CAR-T细胞疗法LB2501在复发或难治性B细胞非霍奇金淋巴瘤患者中的初步临床数据。通过在患者体内直接生成CAR-T细胞，该方法有望简化治疗流程，并提升传统CAR-T细胞疗法难以覆盖患者的可及性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306685.HKD","HK0000306701.USD","BK1576","BK4505","HK0000320264.USD","VXUS","LEGN","BK4139","HK0000320223.HKD","BK1583","BK4585","BK1141","BK4588","01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640653946","title":"热门中概股普涨 传奇生物(LEGN)涨 8.98% 三倍做多富时中国ETF涨8.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640653946","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640653946?lang=zh_cn&edition=full","pubTime":"2026-06-02 21:42","pubTimestamp":1780407750,"startTime":"0","endTime":"0","summary":"金吾财讯 | 热门中概股普涨，传奇生物 涨 8.98%，禾赛 涨 7.54%，理想汽车 涨 6.12%，阿里巴巴 涨 4.96%，小鹏集团 涨 4.88%，京东 涨 4.54%，金山云 涨 3.75%，万国数据 涨 3.44%，小马智行 涨 2.78%，三倍做多富时中国ETF指数涨8.40%。消息发布后，腾讯控股港股股价飙升 10.46%，创 2022 年 11 月以来最大单日涨幅。恒生科技指数大涨 4.72%，恒生指数涨 2.52% 站上 26000 点，国企指数涨 3%。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210625/MmNlMmI2NWNjNWI2MzQ2MDk3MTI0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/MmNlMmI2NWNjNWI2MzQ2MDk3MTI0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301087","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0149721374.USD","LU1211504680.USD","00700","LU0823426480.USD","IE0003851619.USD","LU2251237306.USD","LU1242518857.USD","LU0456842615.SGD","LU0314109678.HKD","LU1224709979.USD","LU0640798160.USD","LU0348805143.USD","IE00BQXX3C00.GBP","LU0561508036.HKD","BK1526","LU1048484197.HKD","LU0106259558.USD","LU0501845795.SGD","LU0359202008.SGD","LU0577902538.SGD","LU0329678170.USD","LU0173614495.USD","LU0880133367.SGD","LU0791591158.USD","SG9999000327.SGD","LU0011963245.USD","LU0862451753.SGD","SG9999006514.SGD","LU2237443895.HKD","LU0823041008.USD","BK1609","LU0117841782.USD","LU0164880469.USD","LU0608807433.USD","LU0882747503.HKD","HTCD.SI","LU0084288322.USD","LU0488056044.USD","LU0048597586.USD","LU1282649067.USD","LU0348825331.USD","LU1808992512.USD","LU0594300419.USD","IE00BQXX3D17.EUR","LU1439103000.SGD","IE00B8HQ1Z84.USD","IE00B031HY20.USD","BK1502","SG9999002828.SGD","LU0261947096.USD","LU0577902298.EUR","LU2008162690.USD","LU0047713382.USD","LU0898667661.SGD","02525","LU0463099449.HKD","LU0348735423.USD","LU0797268264.HKD","LU2462611646.USD","LU0648948544.HKD","LU0823413587.USD","LU1691799644.USD","IE0003895053.USD","LU0117844026.USD","HK0001040143.USD","FXP","SGXZ81514606.USD","LU0259732245.USD","LU0886674414.USD","BK1589","LU1675838814.USD","LU2177674079.SGD","LU0293314216.USD","LU0543330483.HKD","LU0229945570.USD","SG9999018865.SGD","HK0000306701.USD","LU0359201612.USD","LU0469268626.HKD","LU1226288253.USD","LU0348784397.USD","LU1102505762.USD","LU0048388663.USD","LU1105468828.SGD","SGXZ31699556.SGD","LU2237443549.SGD","LU0210533765.USD","LU0163747925.USD","LU1810669033.SGD","TCEHY","IE0001KFT4U8.USD","HK0000320264.USD","LU2257852520.SGD","YXI","LU0211331839.USD","LU0345769128.USD","LU0067412154.USD","BK1608","IE00B067MR52.USD","LU1868838027.USD","LU2097828714.EUR","LU2362541273.HKD","LU0181495838.USD","HK0000320223.HKD","LU0708995153.HKD","LU1642822792.SGD","LU0823413660.USD","LU0456846285.SGD","SGXZ51526630.SGD","LU0043850808.USD","LU0348783233.USD","LU0979878070.USD","LU1064131003.USD","82822","IE0008369823.USD","LU1115378108.SGD","LU0593848301.USD","YINN","LU0650527681.SGD","LU0455707207.USD","IE0032834883.USD","LU0873338254.USD","LU0890818403.SGD","LU2097828805.USD","LU0264606111.USD","LU0516423174.USD","LU0106959298.USD","LU0672654166.SGD","LU0049112450.USD","BK1610","LU1961090484.USD","SG9999001051.SGD","LU0577902454.USD","SG9999013353.USD","LU2362541513.USD","LU0210527791.USD","LU0188438112.USD","LU0651947912.USD","LU1785774172.SGD","LU1883866441.USD","LU1196710864.SGD","82843","LU0231483743.USD","LU1044876610.USD","LU1102505929.USD","LU0096374516.USD","LU1868837565.USD","LU0307460666.USD","LU0543330566.HKD","LU2125910849.SGD","LU0516422952.EUR","BK4139","IE00B97KM107.HKD","LU2476274308.USD","IE0034224299.USD","HK0000914660.USD","SG9999001069.SGD","LU1226288170.HKD","LU0165289439.USD","LU0235996351.USD","HK0000914686.HKD","LU1242518931.SGD","LU1226288097.SGD","LU2045819591.USD","LU0878005551.USD","LU0396098781.USD","LU2237443978.SGD","LU0080751232.USD","LU1769817096.USD","LU0541501648.USD","LU0228367735.SGD","LU0700851271.USD","HK0000306685.HKD","CWEB","LU1323998911.USD","LU0823040885.USD","LU0269904917.USD","LU2039709279.SGD","LU1046422090.SGD","LU1188198961.HKD","LU1813983027.USD","LU0345776255.USD","LU1655091459.SGD","LU0502904849.HKD","LU1251922891.USD","HK0001040168.HKD","LU0441854154.USD","LU2265009873.SGD","BK1586","LU0203345920.USD","LU1226287875.USD","LU2226246903.HKD","LU0061477393.USD","LU0449515922.USD","LU2247934214.USD","LU0315179316.USD","LU2293587155.HKD","LU0683595622.HKD","IE00B29SXG58.USD","LU0326950275.SGD","LU2237443465.HKD","LU0871576103.HKD","LU0531971595.HKD","LU1366334578.USD","LU0128522744.USD","LU0106252389.USD","LU1051768304.USD","LU1951186391.HKD","LU0345775950.USD","LU0737861772.HKD","LU0251144936.SGD","LU0862451837.USD","LU0164865239.USD","IE0003795394.USD","IE0008368411.USD","LU0456827905.SGD","SG9999014906.USD","LU0417516738.SGD","SG9999014898.SGD","LU0143863784.USD","LU0819123356.HKD","LU1956131251.USD","LU0572944931.SGD","LU2242644610.SGD","LU0589944569.HKD","LU0054450605.USD","LU0417516571.SGD","02843","LU1770036033.HKD","LU0633140560.USD","SG9999014880.SGD","SG9999018857.SGD","82823","LU0072913022.USD","LU0289960550.SGD","LU0633140727.USD","LU1051769294.HKD","LU0819121731.USD","IE00B8L5B284.USD","LU2051468812.USD","LU2023250504.SGD","LU0607220059.USD","LU1807302812.USD","LU1282651048.USD","LU0572939691.SGD","LU1734074674.USD","LU0588545730.USD","SGXZ99366536.SGD","LU0192582467.USD","LU2106854487.HKD","BK4124","LU1831875114.USD","LU0918141705.HKD","LU0449509016.USD","LU2125910500.SGD","IE0031814852.USD","LU0823039010.USD","LU1282649141.HKD","LU1196710195.USD","LU0327786744.USD","LU1366334651.USD","LU2251237488.HKD","LU0972618739.USD","LU0345769631.USD","LU2279701549.SGD","LU0127658192.USD","LU0642271901.SGD","LU0791590937.USD","BK4614","LU0605514214.HKD","LU2152927971.USD","LU0214875030.USD","LU0786609619.USD","LU2498475776.HKD","LU0210526637.USD","BK1517","BK1521","LU0821914370.USD","LU1023057109.AUD","LU0107464264.USD","LU0823397103.USD","LU0431992006.USD","LU1733274390.USD","LU1226287792.SGD","LU0608807946.USD","ASHR","LU0320764243.SGD","LU0029874905.USD","SG9999006597.SGD","LU0029875118.USD","LU1720050803.USD","SG9999002463.SGD","SG9999015952.SGD","IE00B0169L03.USD","LU0261950983.USD","LU1688375341.USD","LU0588546209.SGD","LU0326948709.USD","LU0634319403.HKD","LU2317271919.USD","LU0516422440.USD","LU0708995583.HKD","LU0315178854.USD","SG9999000459.SGD","LU0348788117.USD","LU1282651121.HKD","IE00BF5LJ272.USD","LU0370786039.SGD","LU0509642566.USD","LU1328277881.USD","IE0008368742.USD","LU0049853897.USD","IE00B3M56506.USD","LU0164872284.USD","LU1880383366.USD","LU2097828557.USD","LU1282649810.SGD","LU0203347892.USD","LU0414403682.SGD","SG9999000418.SGD","BK4505","LU0329678337.USD","LU0052750758.USD","LU0072462343.USD","SG9999015945.SGD","LU1568876335.HKD","LU2133065610.SGD","LU0149534421.HKD","MCHI","LU0651946864.USD","LU1152091168.USD","02823","LU1568876251.USD","LU1880383440.USD","LU0051755006.USD","LU0169518387.USD","LU0143863198.USD","HK0000352382.USD","LU0328353924.USD","LU2148510915.USD","HK0000151867.HKD","LU1733274473.HKD","SG9999007991.SGD","LU0054237671.USD","IE00BQXX3F31.USD","LU0828237510.HKD","LU1974910355.USD","GB00BDT5M118.USD","SG9999015986.USD","BK4588","LU1993786604.SGD","LU2294711473.HKD","LU1868837722.USD","LU1504937902.USD","LU0588545904.SGD","LU1226287529.USD","SG9999001903.USD","LU0348814723.USD","LU1804176565.USD","LU0828237940.HKD","LU2097828631.EUR","LU0865486749.SGD","LU0516422366.SGD","LU2237443622.USD","LU0918141887.USD","LU1439102457.SGD","IE00B5MMRT66.SGD","LU1282648689.USD","LU2362540622.SGD","SG9999014674.SGD","LU0287142896.SGD","LU0140636845.USD","LU0499858602.USD","LU1196710351.USD","LU0831103253.SGD","BK1516","SG9999014914.USD","DRAG","IE0032431581.USD","SG9999001846.SGD","LU0588545490.SGD","LU0320764755.SGD","LU0132412106.USD","LU0348827113.USD","SG9999001226.SGD","LU1725190679.HKD","LU1515016050.SGD","SG9999004220.SGD","LU2087589342.USD","LU0985320562.USD","SG9999001093.SGD","LU1718418525.SGD","LU1064130708.USD","LU1814569148.SGD","LU0417516902.SGD","LEGN","LU1316542783.SGD","LU1048596156.SGD","LU0541502299.USD","LU1235295612.USD","LU0594300179.USD","LU0784639295.USD","LU1981816686.USD","BK1591","LU1770034418.SGD","LU1629966141.USD","SG9999001689.USD","LU1044875133.USD","BK1095","TCHmain","LU2399975544.HKD","LU2097828474.EUR","IE00BZ08YS42.EUR","LU1152091754.HKD","LU0823397285.USD","LU0577902611.USD","LU0039217434.USD","LU0823038988.USD","IE00B031J352.USD","LU1303224171.USD","BK4585","LU0572940350.SGD","LU0868486357.SGD","FLCH","LU0675040207.SGD","LU0228659784.USD","LU0531970944.HKD","BK1615","LU1960683339.HKD","HXC","LU0359201885.HKD","LU0348783662.USD","HK0000352291.HKD","LU0611395673.USD","LU0348723411.USD","SG9999002562.SGD","IE00B031HW06.USD","LU0211977185.USD","LU2476274720.SGD","LU3063872942.SGD","LU0738912210.USD","LU0737861699.HKD","HSAI","LU0828238088.HKD","SG9999003461.SGD","IE0009570106.USD","LU0320764599.SGD","SGXZ90724238.SGD","ASHS","LU1044874839.SGD","LU0175139822.USD","LU1719994722.HKD","02822","LU1048588211.SGD","LU0499858438.USD","LU0128522157.USD","IE00BGV7N243.SGD","LU0577902371.SGD","LU1917777945.USD","IE00BPRC5H50.USD","LU0196878994.USD","BK1531","LU1769817179.HKD","LU0348816934.USD","BK1618","LU2449936058.SGD","LU1224444064.USD","LU0856984785.SGD","XPP","LU1008478684.HKD","IE00BZ08YT58.USD","IE00B0169N27.USD","IE00B0JY6N72.USD","LU1328615791.USD","LU0384037296.USD","LU0516423091.SGD","LU2778985437.USD","LU0244354667.USD","LU0878004406.USD","LU1481107354.HKD","SG9999017495.SGD","LU0048580855.USD","IE00BZ08YR35.GBP","LU0254981946.USD","LU0540923850.HKD","LU2237443382.USD","LU0823426308.USD","LU1794554557.SGD","SG9999015978.USD","LU0070217475.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193018038","title":"传奇生物：剂量水平2队列实现100%客观缓解率，复发/难治性NHL患者完全缓解率达83.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1193018038","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193018038?lang=zh_cn&edition=full","pubTime":"2026-06-02 21:37","pubTimestamp":1780407440,"startTime":"0","endTime":"0","summary":"传奇生物公布的数据显示，在其研究的剂量水平2队列中，所有六名受试者均观察到客观缓解，客观缓解率达到百分之百。其中，针对复发或难治性非霍奇金淋巴瘤患者，完全缓解率表现尤为突出，在六名患者中有五人实现完全缓解，比例高达83.3%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4505","LEGN","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159258918","title":"传奇生物：数据显示无需淋巴清除化疗或桥接治疗即可实现强劲的体内CAR-T扩增","url":"https://stock-news.laohu8.com/highlight/detail?id=1159258918","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159258918?lang=zh_cn&edition=full","pubTime":"2026-06-02 21:30","pubTimestamp":1780407043,"startTime":"0","endTime":"0","summary":"传奇生物公布的数据显示，其CAR-T疗法在无需进行淋巴清除化疗或桥接治疗的情况下，仍能在患者体内实现强劲的扩增。这一发现挑战了当前CAR-T治疗的标准预处理方案，可能为患者带来更安全、更便捷的治疗选择。数据揭示了该疗法独立于传统化疗支持而发挥效力的潜力，为未来优化治疗流程提供了新的方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEGN","BK4139","BK4588","BK4585","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638527636","title":"港股异动 | 金斯瑞生物科技(01548)涨超5% 近日联营传奇生物多项研究成果于2026年ASCO年会发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2638527636","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638527636?lang=zh_cn&edition=full","pubTime":"2026-05-27 09:57","pubTimestamp":1779847023,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技涨超5%，截至发稿，涨5.35%，报13.98港元，成交额5063.58万港元。消息面上，近日，金斯瑞生物科技发布公告，公司联营公司传奇生物科技股份有限公司已于2026年5月21日向美国证券交易委员会提交6-K表格并发布新闻稿，宣布在2026年美国临床肿瘤学会年会上发表多项研究成果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446407.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","HK0000320223.HKD","BK4505","HK0000306685.HKD","HK0000320264.USD","LEGN","VXUS","HK0000306701.USD","BK4588","01548","BK4585","BK4139","BK1583","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635574510","title":"传奇生物(LEGN)盘中上涨1.71% 机构指Carvykti为多发性骨髓瘤领域同类最佳CAR-T疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2635574510","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635574510?lang=zh_cn&edition=full","pubTime":"2026-05-14 22:21","pubTimestamp":1778768489,"startTime":"0","endTime":"0","summary":"金吾财讯 | 传奇生物 盘中走高，截至发稿，报29.18美元，涨幅1.71%，成交额1524.93万美元。消息面上，RBC Capital Marketsu研究认为，传奇生物报告了Carvykti在第一季度的稳健表现，同时市场关注点正逐渐转向体内管线项目，预计未来几个月将有潜在更新，并在2026年之前取得更多的临床进展。分析师表示：“我们将Carvykti视为多发性骨髓瘤领域的同类最佳CAR-T疗法”，并补充称该疗法有望在2026年实现销售额达到$27.5亿，并在销售峰值时达到$80亿。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/NTE3MzYyMzA2NDI2MjU=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NTE3MzYyMzA2NDI2MjU=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300469","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4585","CAR","BK4022","LEGN","BK4230","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635227658","title":"港股异动 | 金斯瑞生物科技(01548)涨超5% 联营传奇生物一季度亏损收窄、CARVYKTI®净销售额增六成","url":"https://stock-news.laohu8.com/highlight/detail?id=2635227658","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635227658?lang=zh_cn&edition=full","pubTime":"2026-05-13 09:34","pubTimestamp":1778636055,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技(01548)涨超5%，截至发稿，涨5.03%，报15.23港元，成交额2969.6万港元。消息面上，金斯瑞生物科技联营传奇生物隔夜股价大涨超10%。传奇生物昨日公布了2026年第一季度未经审计的财务业绩及公司主要重点，与2025年第一季度相比，CARVYKTI®在2026年第一季度的净销售额增长62%，达到约5.97亿美元。其中美国市场净销售额增长36%，美国以外的市场净销售额增长222%。此外，公司截至2026年3月31日止三个月的净亏损收窄至5430万美元，而去年同期净亏损为1.010亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01548","BK4505","BK4585","LEGN","BK1583","HK0000306701.USD","VXUS","BK4588","BK4139","BK1141","BK1576","HK0000306685.HKD","HK0000320223.HKD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176686384","title":"传奇生物公布截至2026年3月31日现金、现金等价物及定期存款达8.346亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176686384","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176686384?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:01","pubTimestamp":1778583704,"startTime":"0","endTime":"0","summary":"传奇生物近日披露了其最新的财务状况。截至2026年3月31日，该公司持有的现金、现金等价物以及定期存款总额达到了8.346亿美元。\n这一数据展现了公司在特定时间点的财务实力与流动性水平。充足的现金储备为公司的研发活动、业务拓展及日常运营提供了坚实的资金保障。在生物科技领域，持续且大量的资金投入对于推进管线项目、应对市场挑战至关重要。因此，这笔可观的资金头寸无疑为公司的长期战略发展奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4505","LEGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634923334","title":"传奇生物Q1 2026财报前瞻：CARVYKTI销售额预计约5.97亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634923334","media":"环球市场播报","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634923334?lang=zh_cn&edition=full","pubTime":"2026-05-11 23:22","pubTimestamp":1778512920,"startTime":"0","endTime":"0","summary":"传奇生物将于5月12日周二盘前发布2026年第一季度财报，市场普遍关注其核心产品CARVYKTI的销售表现及公司盈利能力进展。根据已公布的初步数据，CARVYKTI第一季度净贸易销售额约为5.97亿美元。 CARVYKTI的销售增长仍是本季最大看点。尽管第一季度通常受季节性因素影响，但CAR-T疗法的需求依然强劲，此前公布的约5.97亿美元初步数据远超市场预期。此外，公司将在财报发布后举行电话会议，管理层对全年业绩指引及CAR-T竞争格局的看法备受关注。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-11/doc-inhxpxwx1741655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LEGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143439572","title":"财报前瞻｜传奇生物本季度营收预计同比增58.58%，机构观点偏积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1143439572","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143439572?lang=zh_cn&edition=full","pubTime":"2026-05-05 08:47","pubTimestamp":1777942061,"startTime":"0","endTime":"0","summary":"传奇生物将于2026年05月12日发布新财季业绩，市场聚焦收入高增长与利润修复节奏。一致预期显示，本季度公司营收预计为3.07亿美元，同比增长58.58%；预计调整后每股收益为-0.02美元，同比增长90.53%；预计息税前利润为-324.34万美元，同比增长95.45%，若无法获取毛利率、净利润或净利率的预测数据则不展示。发展前景最大现有业务仍集中在“许可和协作”，上季度实现收入10.29亿美元，同比增长未披露，但结构性贡献显著，显示现金流与业绩韧性。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜传奇生物本季度营收预计同比增58.58%，机构观点偏积极","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629604010","title":"股价5日拉升逾40%，礼来的70亿美元豪赌让市场看清低估的传奇生物(LEGN.US)？","url":"https://stock-news.laohu8.com/highlight/detail?id=2629604010","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629604010?lang=zh_cn&edition=full","pubTime":"2026-04-22 09:57","pubTimestamp":1776823046,"startTime":"0","endTime":"0","summary":"强劲的业绩兑现显然成为传奇生物股价的强心剂，带动传奇生物股价在4月14日和15日连续拉升。但相比亮眼业绩的助推，礼来4月20日宣布以最高70亿美元总对价收购Kelonia的消息带来的市场情绪波动似乎才是此轮传奇生物股价大幅拉升的关键催化剂。在可评估的5名患者中，ORR达100%，CR达80%。然而在这种背景下，传奇生物截至今年4月17日的市值仅39.16亿美元，仅比此次礼来向Kelonia支付的首付款高不到7亿美元，离该交易总对价70亿美元相差甚远。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431710.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","LU1712237335.SGD","IE0005OL40V9.USD","LU2236285917.USD","LU1551013425.SGD","SGXZ81514606.USD","IE0004445239.USD","SGXZ99366536.SGD","IE00BKDWB100.SGD","LU2896262040.SGD","LU0466842654.USD","LU0316494557.USD","LU2108987350.USD","LU2237443895.HKD","IE00BK4W5L77.USD","LU2552382058.USD","LU2471134879.HKD","LU0109391861.USD","LU0385154629.USD","LU1064131342.USD","LU2417539215.USD","BK4534","LU0256863811.USD","IE00BKPKM429.USD","IE0004445015.USD","IE00B1BXHZ80.USD","LU0289739699.SGD","SG9999014914.USD","LU0417517546.SGD","LU1145028129.USD","LU0061475181.USD","IE00B4JS1V06.HKD","LU2023250504.SGD","LU2168564149.EUR","IE0001KFT4U8.USD","IE00BWXC8680.SGD","LU0094547139.USD","LU1720051108.HKD","LU2023250330.USD","LU2213496289.HKD","LU2491050154.USD","SG9999001176.SGD","LU2089284900.SGD","ELIL","SG9999014880.SGD","LU2271345857.HKD","LU0096364046.USD","LU0266013472.USD","SG9999014898.SGD","IE00B7KXQ091.USD","SGXZ31699556.SGD","IE00B2B36J28.USD","LU2461242641.AUD","LU0882574055.USD","LU0823434740.USD","BK4599","IE00B4R5TH58.HKD","IE00BK4W5M84.HKD","LU0058720904.USD","LU0234572021.USD","LU0079474960.USD","LU2746668974.SGD","SG9999018857.SGD","LU0225283273.USD","LU2087625088.SGD","SG9999013999.USD","IE0009355771.USD","LU2106854487.HKD","LU2168564495.EUR","LU1035775433.USD","LU0689472784.USD","LU2357305700.SGD","LU0820561818.USD","IE00BJLML261.HKD","LU1989771016.USD","LU2023251221.USD","LU2237443622.USD","LU0820562030.AUD","BK4585","LU0456855351.SGD","LU2756315664.SGD","LU0354030511.USD","LU0122379950.USD","LU1023059063.AUD","SG9999018865.SGD","BK4516","LLII","LU0238689110.USD","LU1974910355.USD","IE00BJJMRY28.SGD","LU0133085943.USD","LU2211815571.USD","LEGN","LU2361044949.HKD","ELIS","LU1917777945.USD","LU1868836914.USD","LU2361044865.SGD","SG9999014906.USD","LU1069344957.HKD","LU0210536198.USD","BK4505","LU0006306889.USD","LU0203201768.USD","IE00BN29S564.USD","LU0640476718.USD","LU0964807845.USD","LU1548497426.USD","LU2237438978.USD","LU2491049909.HKD","LU2237443549.SGD","BK4533","LU0432979614.USD","LU2471134952.CNY","LU0471298694.HKD","LU0882574139.USD","SG9999015978.USD","LU0889565916.HKD","LU1623119135.USD","LU1983299246.USD","LU0109394709.USD","LU2602419157.SGD","LU2746668461.USD","LU2360106947.USD","LU2063271972.USD","LU1057294990.SGD","LU1061106388.HKD","IE00BJT1NW94.SGD","LU2468319806.SGD","BK4581","LU1868836591.USD","SG9999017495.SGD","LU2111349929.HKD","BK4588","LU0787776722.HKD","IE00BFSS8Q28.SGD","SG9999001176.USD","LU2112291526.USD","LU1232071149.USD","LU1814569148.SGD","LU1868837136.USD","LU2756315318.SGD","LU2237443978.SGD","LU0158827781.USD","LU2168563687.JPY","LU2552382215.SGD","LU2028103732.USD","LLYZ","IE00BFSS7M15.SGD","LU2456880835.USD","LU1323610961.USD","LU1804176565.USD","LU0943347566.SGD","IE00BJJMRZ35.SGD","IE00BJJMRX11.SGD","LU2237443465.HKD","LU0114720955.EUR","LLYX","LU1366192091.USD","LU1988902786.USD","BK4139","LU2552382132.HKD","LU2089984988.USD","LU2264538146.SGD","SGXZ57979304.SGD","LU0786609619.USD","LU1127390331.HKD","LU2089283258.USD","LU2168564065.EUR","LU0823416689.USD","LU2471134796.USD","LU2265009873.SGD","LU0256863902.USD","LU1280957306.USD","LU1868836757.USD","LU0672654240.SGD","LU2324357040.USD","LU2361045086.USD","LU2168564222.USD","LU0323591593.USD","LU1291159041.SGD","LU1629891620.HKD","LU0158827948.USD","LU2462157665.USD","LU0353189680.USD","LU0708995401.HKD","LU2491050071.SGD","SG9999015945.SGD","LU0820561909.HKD","LU1093756325.SGD","LU0354030438.USD","LU1093756168.USD","LU0471298777.SGD","LU0353189763.USD","LU2750360997.AUD","SGXZ51526630.SGD","LU0106261372.USD","LU1720051017.SGD","SG9999015952.SGD","LU0203202063.USD","LU0823434583.USD","LU0320765059.SGD","IE00B1XK9C88.USD","LU2237443382.USD","LU1551013342.USD","LU0683600562.USD","LU1868837300.USD","SG9999015986.USD","LU0320765992.SGD","LU0198837287.USD","LU2471134523.USD","LU1267930730.SGD","LU2750360641.GBP","IE00B775H168.HKD","GB00BDT5M118.USD","IE0002141913.USD","LU0097036916.USD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620412370","title":"港股异动 | 金斯瑞生物科技(01548)涨超5% 年度收益同比增加61.4% 传奇生物亏损大幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2620412370","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620412370?lang=zh_cn&edition=full","pubTime":"2026-03-17 11:15","pubTimestamp":1773717332,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技涨超5%，截至发稿，涨3.24%，报66.95港元，成交额6281.35万港元。消息面上，3月15日，金斯瑞生物科技发布截至2025年12月31日止年度业绩，该集团期内取得收益9.6亿美元，同比增加61.4%；母公司拥有人应占亏损5.33亿美元，同比盈转亏；每股基本亏损24.58美分。华泰证券指出，金斯瑞生物科技2025年业绩符合预期，各主要业务板块展现稳健增长或扭亏态势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","01548","HK0000320264.USD","HK0000320223.HKD","LEGN","HK0000306685.HKD","BK4139","BK1576","VXUS","HK0000306701.USD","BK4585","BK4505","BK4588","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618718200","title":"【新股IPO】据报传奇生物计划今年在香港上市 集资3亿至4亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618718200","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618718200?lang=zh_cn&edition=full","pubTime":"2026-03-12 17:07","pubTimestamp":1773306468,"startTime":"0","endTime":"0","summary":"金吾财讯 | 有报道引述消息人士称，金斯瑞生物科技(01548)联营公司传奇生物计划今年在香港上市，集资3亿至4亿美元。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/MjI2MDllNmU0MDE4OTQyNzM4NTczYjJhMDY4OTU0MjU2ODIwNTMx.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MjI2MDllNmU0MDE4OTQyNzM4NTczYjJhMDY4OTU0MjU2ODIwNTMx.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976400","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548","BK4139","HK0000306685.HKD","BK1576","BK4585","HK0000320264.USD","BK4588","BK1141","HK0000306701.USD","BK1583","LEGN","BK4505","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618956896","title":"传奇生物CAR-T销售放量，盈利拐点将至下的喜与忧","url":"https://stock-news.laohu8.com/highlight/detail?id=2618956896","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618956896?lang=zh_cn&edition=full","pubTime":"2026-03-10 21:25","pubTimestamp":1773149131,"startTime":"0","endTime":"0","summary":"3月10日，传奇生物（NASDAQ:LEGN）发布了截至2025年12月31日的第四季度及全年财务业绩。这份成绩单不仅标志着公司核心产品CARVYKTI?（西达基奥仑赛）首次实现产品线盈利，也展现出国产CAR-T出海标杆从“烧钱扩张”向“自我造血”转型的关键一跃。财报显示，CARVYKTI?在2025年第四季度实现净销售额约5.55亿美元，全年销售额达18.87亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103667731683.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103667731683.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4505","CAR","BK4588","BK4230","BK4585","LEGN","BK4022","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177311064","title":"财报前瞻｜传奇生物营收预计增71.50%，市场观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1177311064","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177311064?lang=zh_cn&edition=full","pubTime":"2026-03-03 10:13","pubTimestamp":1772503992,"startTime":"0","endTime":"0","summary":"传奇生物将于2026年03月10日发布最新季度财报，市场普遍聚焦许可协作收入的延续性、亏损收窄与核心产品商业化节奏对单季表现的拉动。市场一致预期本季度公司营收约3.07亿美元，同比增长71.50%；调整后每股收益预计为-0.11，同比增长64.00%；息税前利润预计为-2,018.35万美元，同比增长75.75%，当前未见关于毛利率、净利润或净利率的权威一致预测。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜传奇生物营收预计增71.50%，市场观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614852749","title":"吉利德78亿美元全面收购Arcellx公司获得BCMA-CAR T疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2614852749","media":"药企市值评估","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614852749?lang=zh_cn&edition=full","pubTime":"2026-02-27 20:46","pubTimestamp":1772196399,"startTime":"0","endTime":"0","summary":"近日，吉利德宣布以78亿美元估值全面收购其2022年就牵手合作的伙伴公司Arcellx，消息宣布当天Arcellx股价大涨近80%。以下文字写于2024年11月，标题《再论Arcellx公司的BCMA-CAR T疗法》我又仔细研读了Arcellx公司2023年年报，发现这个公司在技术上还是有一些新东西的。目前传奇生物是70亿美元市值出头，Arcellx甚至有追平的趋势。以下文字写于2023年11月，标题《Arcellx公司的BCMA-CART似乎数据不错，但是临床进展太滞后了》近日，","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227213733a4379541&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227213733a4379541&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","CAR","LEGN","BK4139","BK4230","BK4505","BK4022","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.legendbiotech.com","stockEarnings":[{"period":"1week","weight":-0.0946},{"period":"1month","weight":-0.2232},{"period":"3month","weight":0.4912},{"period":"6month","weight":0.1475},{"period":"1year","weight":-0.3181},{"period":"ytd","weight":0.2456}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1111},{"period":"6month","weight":0.0877},{"period":"1year","weight":0.2063},{"period":"ytd","weight":0.1071}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"传奇生物科技有限公司是一家全球性的临床级生物制药公司，致力于肿瘤和其他适应症的新药的发现和开发。该公司的差异化技术、全球开发和制造战略及专业知识使其能够针对高未满足需求的适应症生成、测试和制造下一代细胞疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.047546},{"month":2,"riseRate":0.5,"avgChangeRate":0.01776},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.03136},{"month":4,"riseRate":0.833333,"avgChangeRate":0.112839},{"month":5,"riseRate":0.5,"avgChangeRate":0.032168},{"month":6,"riseRate":1,"avgChangeRate":0.13586},{"month":7,"riseRate":0.571429,"avgChangeRate":0.02013},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.05555},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.023313},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.000245},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.020911},{"month":12,"riseRate":0,"avgChangeRate":-0.105244}],"exchange":"NASDAQ","name":"传奇生物","nameEN":"Legend Biotech"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"传奇生物(LEGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供传奇生物(LEGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"传奇生物,LEGN,传奇生物股票,传奇生物股票老虎,传奇生物股票老虎国际,传奇生物行情,传奇生物股票行情,传奇生物股价,传奇生物股市,传奇生物股票价格,传奇生物股票交易,传奇生物股票购买,传奇生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"传奇生物(LEGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供传奇生物(LEGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}